Furthermore, we established that the PRMT7-SOX9 axis plays a crucial role in NSCLC progression both in vitro and in vivo, highlighting its potential as a promising therapeutic target (Fig. 7k). Here, SOX9 is linked to non-small cell lung carcinoma.